-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
HIV Integrase
CAS No. | Product Name | Inquiry |
---|---|---|
Dolutegravir-d6-sodiumDolutegravir-d6 sodium (S/GSK1349572-d6 sodium) is the deuterium labeled Dolutegravir sodium. Dolutegravir sodium (S/GSK1349572 sodium) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir sodium (S/GSK1349572 sodium) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir sodium (S/GSK1349572 sodium) retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM). |
||
Elvitegravir-d8Elvitegravir-d8 is deuterium labeled Elvitegravir. Elvitegravir (GS-9137, JTK-303) is an HIV integrase inhibitor for HIV-1 IIIB , HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM in cell-free assays, respectively. |
||
HIV-1-protease-IN-6HIV-1 protease-IN-6 (compound 17d) is a potent HIV-1 protease inhibitor, with an IC50 of 21 pM and a Ki of 4.7 pM, respectively. HIV-1 protease-IN-6 exhibits potent antiviral activity to DRV (darunavir)-resistant variant, even more than wild.type virus |
||
HIV-1-protease-IN-7HIV-1 protease-IN-7 (compound 16) is an orally active HIV-1 protease inhibitor (IC50=3.52 nM, EC50=37 nM). |
||
HIV-Protease-Substrate-1-TFAHIV Protease Substrate 1 TFA, a fiuorogenic HIV protease substrate, can be used to study enzymatic activity of HIV protease. |
||
1051375-19-9 |
Dolutegravir sodiumDolutegravir sodium salt is a HIV integrase inhibitor(IC50= 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H. |
|
871038-72-1 |
Raltegravir Potassium SaltRaltegravir is a potent, selective, and orally bioavailable inhibitor of HIV integrase (IC50 = 15 nM). It is metabolized primarily by uridine diphosphate glucuronosyltransferase 1A. Raltegravir has long-term efficacy and safety in managing HIV-1 infection in adults, children, and adolescents. |
|
1051375-16-6 |
DolutegravirDolutegravir is a two-metal-binding HIV-1 integrase inhibitor with IC50 of 2.7 nM, with modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H. It blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). |
|
697761-98-1 |
ElvitegravirElvitegravir is an HIV-1 integrase strand transfer inhibitor (INSTI) for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively. |
|
1051375-10-0 |
Cabotegravir (GSK744, GSK1265744)Cabotegravir (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor against a broad range of HIV subtypes, and inhibits the HIV-1 integrase catalyzed strand transfer reaction with IC50 of 3.0 nM. Phase 2. |
|
1807988-02-8 |
Bictegravir sodiumBictegravir sodium is a HIV-1 integrase strand transfer inhibitor that is derived from the drug dolutegravir. |
|
518048-05-0 |
RaltegravirRaltegravir is a potent integrase (IN) inhibitor used as an antiretroviral medication for the treatment of HIV infections. |
|
1611493-60-7 |
BictegravirBictegravir is a novel, potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM for strand transfer activity. Bictegravir is a drug of the integrase inhibitor class that was copied from Dolutegravir by scientists at Gilead Sciences. Bictegravir also inhibits HIV-1 viral infection in MT-2 and MT-4 cells, CD4+ T cells, and macrophages (EC50s = 1.5, 2.5, 1.5, and 6.6 nM, respectively) without exhibiting cytotoxicity (CC50s = 10.3, 3.7, 13, and 29.8 μM, respectively). In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection. |
※ Please kindly note that our services are for research use only.